EUVIMEDEUVIMED entdecken
Crossref

A triptolide-associated prognostic model for personalized treatment stratification in pancreatic ductal adenocarcinoma

HongMing Xie, Mingjun Deng, HongBiao He, JieBin Liang, JiaXuan Li

Medical Oncology · 04.11.2026 · 43 (12)

DOI: 10.1007/s12032-026-03430-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Oncology, online erschienen am 04.11.2026. Verfasst von HongMing Xie und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Zhongshan Chenxinghai Hospital of Integrated Traditional Chinese and Western Medicine, Zhongshan, 528415, Guangdong, …. Hauptthemen laut MEDLINE: Phenanthrenes, Diterpenes, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Zhongshan Traditional Chinese Medicine Heritage and Innovation Development Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) lacks effective stratification tools to guide therapy. This study explores the potential of triptolide-associated biology in developing a prognostic model for risk stratification and treatment guidance. By integrating computational target predictions with TCGA and ICGC transcriptomic cohorts, we identified differentially expressed triptolide-associated genes. A gene prognostic signature was developed using Cox regression and SHAP-based feature ranking, followed by comprehensive immune landscape and in silico drug-sensitivity profiling. We identified a core six-gene prognostic signature comprising AADAC, BTNL9, ADGRF1, AQP2, F5, and H2AC6. This model demonstrated exceptional predictive accuracy, with 1-, 3-, and 5-year AUC values of 0.759, 0.748, and 0.741 in the training set, and consistent performance in the validation cohort (0.626, 0.677, and 0.703). High-risk patients were characterized by a classic “immune-cold” microenvironment, showing enrichment of M0 macrophages and upregulated immune checkpoints (BTLA, PDCD1, TIGIT). TIDE analysis further revealed that high-risk patients exhibited an “immune-excluded” phenotype characterized by elevated Exclusion and MDSC scores. Furthermore, high-risk patients showed higher sensitivity to paclitaxel and erlotinib, while low-risk patients were more responsive to axitinib and metformin. Molecular docking confirmed stable, high-affinity binding between triptolide and all six target proteins, providing a biophysical basis for the model. Single-cell analysis revealed that the six genes are primarily expressed in endothelia, ductal cells and acinar cells. IHC staining confirmed an enhancement in AADAC, AQP2, ADGRF1, and H2AC6 protein levels in PDAC lesions. This six-gene signature serves as a prognostic model for PDAC risk stratification, with its constituent genes computationally predicted to interact with triptolide, provideing a testable hypothesis for future mechanistic exploration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhenanthrenesDiterpenesCarcinoma, Pancreatic DuctalPancreatic NeoplasmsAntineoplastic Agents, AlkylatingHumansEpoxy CompoundsPrognosisPrecision MedicineBiomarkers, TumorFemaleGene Expression Profiling

Stichwörter der Autor:innen

Immune microenvironmentPancreatic ductal adenocarcinomaPersonalized treatmentPrognostic modelTriptolide

Substanzen

triptolidePhenanthrenesEpoxy CompoundsDiterpenesAntineoplastic Agents, AlkylatingBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Gastroenterology, Zhongshan Chenxinghai Hospital of Integrated Traditional Chinese and Western Medicine, Zhongshan, 528415, Guangdong, China.
  • Department of Pharmacy, Zhongshan Chenxinghai Hospital of Integrated Traditional Chinese and Western Medicine, Zhongshan, 528415, Guangdong, China.
  • Department of Gastroenterology, Zhongshan Chenxinghai Hospital of Integrated Traditional Chinese and Western Medicine, Zhongshan, 528415, Guangdong, China. hcoco_001@163.com.

Förderung

  • Zhongshan Traditional Chinese Medicine Heritage and Innovation Development Research Program

Zitieren

APA

Xie, H., Deng, M., He, H., Liang, J., & Li, J. (2026). A triptolide-associated prognostic model for personalized treatment stratification in pancreatic ductal adenocarcinoma. Medical Oncology, 43(12). https://doi.org/10.1007/s12032-026-03430-3

Vancouver

Xie H, Deng M, He H, Liang J, Li J. A triptolide-associated prognostic model for personalized treatment stratification in pancreatic ductal adenocarcinoma. Medical Oncology. 2026;43(12). doi:10.1007/s12032-026-03430-3

BibTeX
@article{Xie2026,
  author = {Xie, HongMing and Deng, Mingjun and He, HongBiao and Liang, JieBin and Li, JiaXuan},
  title = {A triptolide-associated prognostic model for personalized treatment stratification in pancreatic ductal adenocarcinoma},
  journal = {Medical Oncology},
  year = {2026},
  volume = {43},
  number = {12},
  doi = {10.1007/s12032-026-03430-3}
}
Kostenlos starten →